vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Essent Group Ltd. (ESNT). Click either name above to swap in a different company.
Essent Group Ltd. is the larger business by last-quarter revenue ($312.4M vs $180.9M, roughly 1.7× AVANOS MEDICAL, INC.). Essent Group Ltd. runs the higher net margin — 49.6% vs -0.7%, a 50.3% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -0.8%). Essent Group Ltd. produced more free cash flow last quarter ($848.7M vs $21.3M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 2.3%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Essentra PLC is a supplier of plastic and fibre products. The company operates internationally from headquarters in Kidlington, Oxfordshire. It is listed on the London Stock Exchange.
AVNS vs ESNT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $312.4M |
| Net Profit | $-1.3M | $155.0M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | 59.1% |
| Net Margin | -0.7% | 49.6% |
| Revenue YoY | 0.7% | -0.8% |
| Net Profit YoY | 99.7% | -7.7% |
| EPS (diluted) | $-0.02 | $1.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $312.4M | ||
| Q3 25 | $177.8M | $311.8M | ||
| Q2 25 | $175.0M | $319.1M | ||
| Q1 25 | $167.5M | $317.6M | ||
| Q4 24 | $179.6M | $315.0M | ||
| Q3 24 | $170.4M | $316.6M | ||
| Q2 24 | $171.7M | $312.9M | ||
| Q1 24 | $166.1M | $298.4M |
| Q4 25 | $-1.3M | $155.0M | ||
| Q3 25 | $-1.4M | $164.2M | ||
| Q2 25 | $-76.8M | $195.3M | ||
| Q1 25 | $6.6M | $175.4M | ||
| Q4 24 | $-397.3M | $167.9M | ||
| Q3 24 | $4.3M | $176.2M | ||
| Q2 24 | $1.8M | $203.6M | ||
| Q1 24 | $-900.0K | $181.7M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | 59.1% | ||
| Q3 25 | 0.1% | 63.9% | ||
| Q2 25 | -42.6% | 72.4% | ||
| Q1 25 | 6.1% | 65.2% | ||
| Q4 24 | -233.0% | 61.9% | ||
| Q3 24 | 7.0% | 65.6% | ||
| Q2 24 | 3.7% | 76.4% | ||
| Q1 24 | 2.4% | 71.6% |
| Q4 25 | -0.7% | 49.6% | ||
| Q3 25 | -0.8% | 52.7% | ||
| Q2 25 | -43.9% | 61.2% | ||
| Q1 25 | 3.9% | 55.2% | ||
| Q4 24 | -221.2% | 53.3% | ||
| Q3 24 | 2.5% | 55.6% | ||
| Q2 24 | 1.0% | 65.1% | ||
| Q1 24 | -0.5% | 60.9% |
| Q4 25 | $-0.02 | $1.61 | ||
| Q3 25 | $-0.03 | $1.67 | ||
| Q2 25 | $-1.66 | $1.93 | ||
| Q1 25 | $0.14 | $1.69 | ||
| Q4 24 | $-8.64 | $1.59 | ||
| Q3 24 | $0.09 | $1.65 | ||
| Q2 24 | $0.04 | $1.91 | ||
| Q1 24 | $-0.02 | $1.70 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | — |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $5.8B |
| Total Assets | $1.1B | $7.4B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $92.2M | — | ||
| Q1 24 | $75.8M | — |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $5.8B | ||
| Q3 25 | $778.0M | $5.7B | ||
| Q2 25 | $776.3M | $5.7B | ||
| Q1 25 | $839.4M | $5.7B | ||
| Q4 24 | $828.5M | $5.6B | ||
| Q3 24 | $1.2B | $5.6B | ||
| Q2 24 | $1.2B | $5.4B | ||
| Q1 24 | $1.2B | $5.2B |
| Q4 25 | $1.1B | $7.4B | ||
| Q3 25 | $1.1B | $7.4B | ||
| Q2 25 | $1.0B | $7.2B | ||
| Q1 25 | $1.1B | $7.2B | ||
| Q4 24 | $1.2B | $7.1B | ||
| Q3 24 | $1.7B | $7.1B | ||
| Q2 24 | $1.7B | $6.7B | ||
| Q1 24 | $1.7B | $6.6B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $856.1M |
| Free Cash FlowOCF − Capex | $21.3M | $848.7M |
| FCF MarginFCF / Revenue | 11.8% | 271.7% |
| Capex IntensityCapex / Revenue | 3.8% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 5.52× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $1.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $856.1M | ||
| Q3 25 | $14.0M | $215.9M | ||
| Q2 25 | $6.8M | $189.5M | ||
| Q1 25 | $25.7M | $221.6M | ||
| Q4 24 | $57.9M | $861.5M | ||
| Q3 24 | $23.0M | $229.2M | ||
| Q2 24 | $27.8M | $188.7M | ||
| Q1 24 | $-8.0M | $216.9M |
| Q4 25 | $21.3M | $848.7M | ||
| Q3 25 | $7.0M | $210.6M | ||
| Q2 25 | $-4.2M | $188.8M | ||
| Q1 25 | $19.0M | $221.3M | ||
| Q4 24 | $53.1M | $854.8M | ||
| Q3 24 | $20.0M | $228.7M | ||
| Q2 24 | $21.9M | $187.6M | ||
| Q1 24 | $-12.1M | $212.5M |
| Q4 25 | 11.8% | 271.7% | ||
| Q3 25 | 3.9% | 67.5% | ||
| Q2 25 | -2.4% | 59.2% | ||
| Q1 25 | 11.3% | 69.7% | ||
| Q4 24 | 29.6% | 271.3% | ||
| Q3 24 | 11.7% | 72.2% | ||
| Q2 24 | 12.8% | 60.0% | ||
| Q1 24 | -7.3% | 71.2% |
| Q4 25 | 3.8% | 2.4% | ||
| Q3 25 | 3.9% | 1.7% | ||
| Q2 25 | 6.3% | 0.2% | ||
| Q1 25 | 4.0% | 0.1% | ||
| Q4 24 | 2.7% | 2.1% | ||
| Q3 24 | 1.8% | 0.2% | ||
| Q2 24 | 3.4% | 0.3% | ||
| Q1 24 | 2.5% | 1.5% |
| Q4 25 | — | 5.52× | ||
| Q3 25 | — | 1.31× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | 3.89× | 1.26× | ||
| Q4 24 | — | 5.13× | ||
| Q3 24 | 5.35× | 1.30× | ||
| Q2 24 | 15.44× | 0.93× | ||
| Q1 24 | — | 1.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
ESNT
| Mortgage Insurance Segment | $192.4M | 62% |
| Other | $120.0M | 38% |
